289 results match your criteria keratoprosthesis kpro


Short-Term Outcomes of Pediatric Keratoprosthesis With the Near-Complete Conjunctival Flap.

Cornea 2021 Jun;40(6):679-684

Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY.

Purpose: The Boston keratoprosthesis (KPro) has been used for certain indications in pediatric patients with congenital corneal opacities. Here, we describe the use of a near-complete conjunctival flap at the time of Boston type 1 KPro surgery in pediatric patients, with the goal of improving pediatric KPro outcomes.

Methods: We performed a retrospective chart review of 21 eyes from 16 patients who received their first KPro before the age of 18 years at a tertiary care center in Rochester, NY. Read More

View Article and Full-Text PDF

Tear Film Cytokine Profile of Patients With the Boston Keratoprosthesis Type 1: Comparing Patients With and Without Glaucoma.

Invest Ophthalmol Vis Sci 2021 Apr;62(4):20

Department of Ophthalmology, Université de Montréal, Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.

Purpose: Inflammatory cytokines are involved in glaucoma pathogenesis. The purpose is to compare cytokine levels in the tear film of Boston keratoprosthesis (KPro) patients with and without glaucoma, relative to controls, and correlate levels with clinical parameters.

Methods: This cross-sectional study enrolled 58 eyes (58 patients): 41 KPro eyes with glaucoma, 7 KPro eyes without glaucoma, and 10 healthy controls. Read More

View Article and Full-Text PDF

Frozen versus fresh corneal graft carriers in Boston keratoprosthesis surgery: 10-year outcomes.

Can J Ophthalmol 2021 Mar 26. Epub 2021 Mar 26.

Department of Ophthalmology, Centre Hospitalier de l'Université de Montréal, Montréal, Qué.

Objective: To compare 10-year clinical outcomes of frozen versus fresh corneal graft carriers for the Boston Keratoprosthesis type 1 (KPro).

Design: Prospective, non-masked randomized controlled trial.

Participants: Nineteen eyes of 19 patients having undergone Boston KPro type 1 implantation using a fresh or frozen graft carrier. Read More

View Article and Full-Text PDF

Long-term outcomes of Boston keratoprosthesis type I: the Chinese People's Liberation Army General Hospital experience.

Br J Ophthalmol 2021 Mar 5. Epub 2021 Mar 5.

Department of Ophthalmology, General Hospital of People's Liberation Army, Beijing, China

Purpose: To report the long-term outcomes of Boston keratoprosthesis type I (B-KPro type I) implantation in the management of severe ocular surface disorders.

Methods: Retrospective case series. Patients who underwent B-KPro type I implantation at the People's Liberation Army General Hospital were enrolled between March 2011 and September 2019. Read More

View Article and Full-Text PDF

Time to achieve best postoperative visual acuity following Boston keratoprosthesis surgery.

Br J Ophthalmol 2021 Mar 3. Epub 2021 Mar 3.

Ophthalmology, Université de Montréal, Montreal, Quebec, Canada.

Background/aims: To evaluate the time needed for patients with Boston type 1 keratoprosthesis (KPro) to reach their best-corrected visual acuity (BCVA) and all contributing factors.

Methods: We retrospectively reviewed 137 consecutive eyes from 118 patients, measured how long they needed to reach their BCVA and looked at factors that might affect this time duration including patient demographics, ocular comorbidities and postoperative complications.

Results: The mean follow-up was 5. Read More

View Article and Full-Text PDF

Infectious Keratitis After Boston Type 1 Keratoprosthesis Implantation.

Cornea 2021 Feb 24. Epub 2021 Feb 24.

Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, CA; Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran; Ophthalmology Department, Paris University, Cochin Hospital, Paris, France; and Department of Ophthalmology, Centre hospitalier de l'Université de Montréal, Montréal, Québec, Canada.

Purpose: To identify the incidence, risk factors, and outcomes of infectious keratitis after Boston type 1 keratoprosthesis (kpro) implantation.

Methods: Retrospective case series of kpro procedures at the Stein Eye Institute and the Centre Hospitalier de l'Université de Montréal between May 1, 2004, and December 31, 2018. Data were collected regarding ocular history, operative details, postoperative management, microbiologic profile, treatment, and outcomes. Read More

View Article and Full-Text PDF
February 2021

Long-term outcomes following primary versus secondary Boston keratoprosthesis type 1 implantation.

Br J Ophthalmol 2021 Feb 23. Epub 2021 Feb 23.

Department of Ophthalmology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.

Background/aims: To compare long-term outcomes of primary versus secondary (postgraft failure) Boston keratoprosthesis type 1 (KPro) implantation.

Methods: Medical records of patients at the Centre hospitalier de l'Université de Montréal having undergone KPro implantation between 2008 and 2017 were reviewed and included if they had a preoperative Snellen best-corrected visual acuity (BCVA) of 20/100 or worse and a minimum of 5 years of follow-up. Eighty-two eyes were separated into two cohorts (40 primary, 42 secondary KPro) and BCVA, complications and device retention were evaluated between groups. Read More

View Article and Full-Text PDF
February 2021

Glaucoma Risk Factors and Outcomes Following Boston Keratoprosthesis Type 1 Surgery.

Am J Ophthalmol 2021 Jan 22;226:56-67. Epub 2021 Jan 22.

Department of Ophthalmology, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada. Electronic address:

Purpose: To evaluate glaucoma risk factors and associated outcomes of the Boston keratoprosthesis type I (KPro).

Design: Clinical case-control study.

Methods: This is a single-center study of 140 eyes of 118 patients who underwent KPro surgery between October 2008 and March 2017 by a single surgeon. Read More

View Article and Full-Text PDF
January 2021

A Foldable Nonpenetrating Keratoprosthesis: Medium to Long-Term Clinical Results in Patients with Corneal Blindness due to Noninflammatory Anterior Cornea Disease.

Middle East Afr J Ophthalmol 2020 Jul-Sep;27(3):150-155. Epub 2020 Oct 30.

Department of Sidney, Kimmel Medical College with Thomas Jefferson University, Philadelphia, PA, USA.

Purpose: To report the medium to long-term safety and performance outcomes of the KeraKlear nonpenetrating artificial cornea (KeraKlear) as the primary procedure in patients with corneal blindness due to noninflammatory anterior cornea disease.

Methods: Fifteen patients with corneal blindness (preoperative visual acuity [VA] of ≥20/200) due to a non-inflammatory anterior corneal condition were included in this prospective, single-center study. Preoperative diagnoses included corneal scars, keratoconus, and corneal dystrophies. Read More

View Article and Full-Text PDF
January 2021

Endophthalmitis in Eyes With the Boston Type I Keratoprosthesis: Incidence, Recurrence, Risk Factors, and Outcomes.

Cornea 2020 Dec 31;Publish Ahead of Print. Epub 2020 Dec 31.

Department of Ophthalmology, Centre hospitalier de l'Université de Montréal, Montreal, Canada; and Department of Ophthalmology, King Abdulaziz University, Jeddah, Saudi Arabia.

Purpose: To determine the incidence and recurrence of Boston type I keratoprosthesis (KPro)-associated endophthalmitis, and its microbiological profile, risk factors, and outcomes.

Methods: This is a retrospective study of 158 consecutive KPro procedures with a median follow-up of 78.4 months. Read More

View Article and Full-Text PDF
December 2020

Intrinsic Optical Properties of Boston Keratoprosthesis.

Transl Vis Sci Technol 2020 11 3;9(12):10. Epub 2020 Nov 3.

Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.

Purpose: To benchmark the optical performance of Boston Keratoprosthesis (B-KPro).

Methods: Back focal lengths (BFL) of B-KPros for various eye axial lengths were measured using an optical bench, International Organization for Standardization-certified for intraocular lens characterization, and compared against manufacturer's specification. The modulation transfer function (MTF) and the resolution efficiencies were measured. Read More

View Article and Full-Text PDF
November 2020

Automated Keratopigmentation in Boston Type 1 Keratoprosthesis: An Aesthetic Alternative.

Cornea 2020 Dec;39(12):1578-1580

Research Department, Oftalmosalud Institute of Eyes, Lima, Peru.

Two male patients, aged 64 and 55 years old, presented at the cornea department for a Boston type 1 keratoprosthesis (Kpro I) implantation after multiple corneal graft failures. After surgery, they achieved a best corrected visual acuity of 20/200 and 20/150, respectively. However, they manifested photophobia and aesthetic complaints. Read More

View Article and Full-Text PDF
December 2020

Visual Field Characteristics of Type I Boston Keratoprosthesis Patients without Glaucoma.

J Glaucoma 2020 Nov 3;Publish Ahead of Print. Epub 2020 Nov 3.

Department of Ophthalmology and Visual Sciences, Federal University of São Paulo, UNIFESP, São Paulo, Brazil.

Purpose: To determine visual field findings in Boston Type 1-Kpro (BI-Kpro) patients without glaucoma. Characterize normal threshold values and global indices using standard automated perimetry and characterize visual field amplitude using Goldmann's manual perimetry.

Methods: This cross-sectional prospective non-interventional study included patients (n=6 patients, 6 eyes) with BI-KPro who had normal optical coherence tomography and fundoscopic evaluation of the optic disc and retina. Read More

View Article and Full-Text PDF
November 2020

B-scan ultrasound, visual electrophysiology and perioperative videoendoscopy for predicting functional results in keratoprosthesis candidates.

Br J Ophthalmol 2020 Oct 22. Epub 2020 Oct 22.

Department of Ophthalmology and Visual Sciences, Federal University of São Paulo, São Paulo, Brazil

Background/aims: We analysed the ability of B-scan ultrasound, ocular electrophysiology testing and videoendoscopic examination for predicting visual prognosis in Boston Type 1 keratoprosthesis (KPro-1) candidates. Indirect anatomical and electrophysiological findings and results from direct endoscopic evaluations were correlated with postoperative functional data.

Methods: In this prospective and interventional study, we included 13 individuals who had previously been indicated for Kpro-1 surgery. Read More

View Article and Full-Text PDF
October 2020

Mid-term prognosis of type I Boston keratoprosthesis reimplantation.

Br J Ophthalmol 2020 Oct 14. Epub 2020 Oct 14.

Ophthalmology, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, H2X 3E4, Canara

Aim: To examine the mid-term visual and anatomical prognosis of patients who require reimplantation of a second Boston keratoprosthesis type 1 (B-KPro).

Methods: Retrospective observational case series of 122 patients (141 eyes) who received a B-KPro at a single institution were reviewed. Eyes that underwent a second B-KPro were included in the study. Read More

View Article and Full-Text PDF
October 2020

Idiopathic Vitritis after Boston Type 1 Keratoprosthesis Implantation: Incidence, Risk Factors and Outcomes in a Multicentric Cohort.

Ocul Immunol Inflamm 2020 Oct 15:1-7. Epub 2020 Oct 15.

Stein Eye Institute, David Geffen School of Medicine, University of California , Los Angeles, Los Angeles, California, USA.

Purpose: To determine incidence, risks factors for, and outcomes of idiopathic vitritis (IV) after Boston type 1 keratoprosthesis (KPro) implantation.

Methods: Retrospective, consecutive case series. Risk factors were analyzed between IV group and No IV group. Read More

View Article and Full-Text PDF
October 2020

Outcomes and complications of Boston keratoprosthesis type I implantation in unilateral versus bilateral corneal blindness.

Can J Ophthalmol 2021 Apr 28;56(2):130-136. Epub 2020 Sep 28.

Department of Ophthalmology, Centre Hospitalier de l'Université de Montréal, Montreal, Que.

Objective: To compare the outcomes of Boston keratoprosthesis (KPro) type I implantation between patients who are legally blind versus sighted in the contralateral eye.

Design: Single centre retrospective comparative case series.

Participants: Patients who underwent Boston KPro type I implantation between 2008 and 2017. Read More

View Article and Full-Text PDF

Retroprosthetic membrane: A complication of keratoprosthesis with broad consequences.

Ocul Surf 2020 10 9;18(4):893-900. Epub 2020 Sep 9.

Department of Ophthalmology & Visual Sciences, University of Illinois at Chicago, 1855 W. Taylor St. M/C 648, Chicago, IL, 60612, USA. Electronic address:

Keratoprosthesis (KPro) devices have the remarkable ability to restore vision in patients suffering from corneal blindness who are poor candidates for traditional penetrating keratoplasty. However, eyes with KPro can experience various complications, including the development of retroprosthetic membrane (RPM). RPMs reduce visual acuity in patients due to physical obstruction of the visual axis, but studies have shown that RPM can also lead to a variety of other consequences, from melting of the corneal carrier graft to precipitating retinal detachments. Read More

View Article and Full-Text PDF
October 2020

Transmucosal Boston Keratoprosthesis Type I in a Patient With Advanced Ocular Cicatricial Pemphigoid.

Cornea 2020 Dec;39(12):1563-1565

Centro de Oftalmología Barraquer, Barcelona, Spain; and.

Purpose: To describe a novel surgical technique using the Boston Keratoprosthesis (KPro) type I in a patient with advanced ocular cicatricial pemphigoid (OCP) using oral mucosa for covering the prosthesis.

Methods: We present the case of an 85-year-old man previously diagnosed with type 2 diabetes and advanced OCP nonresponsive to immunosuppressive treatment, whose best-corrected visual acuity was light perception and projection in both eyes. After examination, Boston KPro type I in the right eye was contemplated because osteo-odonto KPro and Tibial bone KPro were not feasible because of the patient's osteoporosis and edentulism. Read More

View Article and Full-Text PDF
December 2020

Management of corneal melt in patients with Boston Keratoprosthesis Type 1: Repair versus repeat.

Ocul Surf 2020 10 7;18(4):713-717. Epub 2020 Aug 7.

Department of Ophthalmology, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.

Purpose: To evaluate outcomes of Boston keratoprosthesis (KPro) repair versus repeat KPro as treatment for corneal melt in KPro patients.

Methods: Retrospective study of adult KPro patients with melt managed by KPro repair or repeat KPro by one surgeon (MH-D). Incidence of sight- or globe-threatening complications, risk of recurrence of melt and change in BCVA before and 3 months after the procedure were compared between both treatment groups. Read More

View Article and Full-Text PDF
October 2020

The Search for Antifungal Prophylaxis After Artificial Corneal Surgery-An In Vitro Study.

Cornea 2020 Dec;39(12):1547-1555

The Boston Keratoprosthesis Laboratory, Department of Ophthalmology, Massachusetts Eye & Ear, Boston, MA.

Purpose: To evaluate the antifungal properties of topical antibiotics (already being used successfully to prevent bacterial endophthalmitis) and some promising antiseptics for antifungal prophylaxis in the setting of artificial corneal implantation.

Methods: Several commonly used antibiotics for antimicrobial prophylaxis after artificial corneal implantation, in addition to antiseptics [benzalkonium chloride (BAK), povidone-iodine (PI), and some ionic liquids (ILs)], were tested in vitro against Candida albicans, Fusarium solani, and Aspergillus fumigatus. The time-kill activity was determined. Read More

View Article and Full-Text PDF
December 2020

Recurrent cystoid macular edema following Boston keratoprosthesis type-II implantation: A treatment option.

Indian J Ophthalmol 2020 Aug;68(8):1691-1693

Department of Cornea, Disha Eye Hospitals, Kolkata, West Bengal, India.

A 68-year-old woman with end-stage Stevens-Johnson syndrome developed cystoid macular edema (CME) 3 months following Boston keratoprosthesis type II (KPro-II) implantation and treated with single-dose injection of triamcinolone acetonide (TA) in the inferior peribulbar region. After 14 days, CME resolved completely, and she regained 20/30 vision. Seven months later, she developed recurrent CME. Read More

View Article and Full-Text PDF

Predictive factors of Boston Type I Keratoprosthesis outcomes: A long-term analysis.

Ocul Surf 2020 10 21;18(4):613-619. Epub 2020 Jul 21.

University of Illinois at Chicago, Department of Ophthalmology and Visual Sciences, 1855 W Taylor St, Suite 1.145 (MC 648), Chicago, IL, 60612, USA. Electronic address:

Purpose: To study the long-term visual- and device retention-related outcomes and complications of the Boston Type I Keratoprosthesis (KPro).

Methods: Single-center, retrospective cohort study of all patients undergoing KPro implantation from February 2007 to April 2014 with at least 5 years of follow-up.

Results: 68 eyes from 65 patients underwent KPro implantation during the study period. Read More

View Article and Full-Text PDF
October 2020

Outcomes of the Boston type 1 and the Aurolab keratoprosthesis in eyes with limbal stem cell deficiency.

Br J Ophthalmol 2021 Apr 17;105(4):473-478. Epub 2020 Jun 17.

The Cornea Institute, L V Prasad Eye Institute, Hyderabad, Telangana, India

Purpose: To analyse the outcomes of keratoprosthesis in eyes with limbal stem cell deficiency (LSCD) and to compare the outcomes in two different keratoprosthesis devices.

Methods: This was a single-centre retrospective comparative case series which included 81 eyes of patients with severe bilateral corneal blindness secondary to LSCD. The patients underwent either Boston type 1 keratoprosthesis (Boston Kpro, n=44) or Aurolab keratoprosthesis (AuroKpro, n=37) implantation. Read More

View Article and Full-Text PDF

Treatment of Oculoplastic and Ocular Surface Disease in Eyes Implanted with a Type I Boston Keratoprosthesis in Southern China: A Retrospective Study.

Adv Ther 2020 07 20;37(7):3206-3222. Epub 2020 May 20.

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, 510060, China.

Introduction: This study aimed to describe the clinical features, surgical management of the eyelid and ocular surface, and outcomes of 16 patients implanted with a Boston type I keratoprosthesis (KPro).

Methods: A retrospective, single-center, consecutive case series of 16 patients with Stevens-Johnson syndrome (1), ocular chemical burns (12), and ocular thermal burns (3) implanted with KPro was studied. All subjects were men aged 27-51 years. Read More

View Article and Full-Text PDF

Corneal transplantation outcomes after the extrusion of an intrastromal keratoprosthesis: a pilot study.

Eye Vis (Lond) 2020 8;7:26. Epub 2020 May 8.

Research and Development Department, Calle Cabañal, 1 Edificio Vissum, 03016 Alicante, Spain.

This short report includes 5 eyes of 5 patients (mean age 63.2 ± 12 years) who underwent a tectonic keratoplasty [deep anterior lamellar keratoplasty (DALK) or penetrating keratoplasty (PK)] in order to rehabilitate the eye after the extrusion of the non-perforating keratoprosthesis (Kpro) KeraKlear (KeraMed, USA). The non-perforating Kpro was extruded after a mean period of 21. Read More

View Article and Full-Text PDF

Long-term visual outcomes of the Boston type I keratoprosthesis in Canada.

Br J Ophthalmol 2020 11 17;104(11):1601-1607. Epub 2020 Feb 17.

Department of Ophthalmology, Montreal University, Montreal, Quebec, Canada

Background/aims: To evaluate long-term visual outcomes of Boston type I keratoprosthesis (KPro) surgery and identify risk factors for visual failure.

Methods: Single surgeon retrospective cohort study including 85 eyes of 74 patients who underwent KPro implantation to treat severe ocular surface disease, including limbal stem cell deficiency, postinfectious keratitis, aniridia and chemical burns. Procedures were performed at the Centre hospitalier de l'Université de Montréal from October 2008 to May 2012. Read More

View Article and Full-Text PDF
November 2020

Comparison of the Clinical Efficacy of Boston Keratoprosthesis Type I and Repetitive Penetrating Keratoplasty for Refractory Keratopathy.

J Craniofac Surg 2020 Mar/Apr;31(2):e194-e199

Department of Ophthalmology, the General Hospital of Northern Theater Command, Shenyang, China.

Objective: To compare the clinical efficacy of Boston Keratoprosthesis type I (B-KProI) and penetrating keratoplasty (PKP) for patients with refractory keratopathy after 1failed PKP in China.

Method: The 42 consecutive cases with refractory keratopathy after 1 failed PKP, from July 2010 to December 2014, were divided into 2 groups according to the surgical method: KPro group (n = 21) and PKP group (n = 21). Visual acuity (LogMAR), corneal graft transparency, postoperative complications and corneal graft survival rate were observed. Read More

View Article and Full-Text PDF

Response to comments on: Keratoprosthesis optic and carrier corneal graft "noncontact" as a cause of sterile stromal necrosis in a case of Auro KPro implantation.

Indian J Ophthalmol 2020 01;68(1):267

Advanced Eye Centre, Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

View Article and Full-Text PDF
January 2020